Top Story

FDA grants orphan drug designation to Reolysin for gastric cancer

May 6, 2015

The FDA granted orphan drug designation to pelareorep for the treatment of gastric cancer, the drug’s manufacturer announced today.

In addition to the receipt of orphan drug designation for the treatment of malignant gliomas in April, pelareorep (Reolysin, Oncolytics Biotech) has recently received orphan drug designations for pancreatic, peritoneal, ovarian, and fallopian tube cancers.

FDA News

FDA grants breakthrough therapy designation to venetoclax for CLL with 17p deletion

May 6, 2015
The FDA today granted breakthrough therapy designation to venetoclax for previously treated patients with relapsed or refractory chronic lymphocytic leukemia who harbor…
Industry News

World Cancer Research Fund updates report on liver cancer

May 6, 2015
Individuals who are overweight or obese are at increased risk for liver cancer, but those who consume coffee have a decreased risk, according to a Continuous Update…
In the Journals

Data show nonmelanoma skin cancer rates rose dramatically from 2006 to 2012

May 6, 2015
There was a dramatic rise in incidence rates of skin cancer in the United States from 2006 to 2012, including a 35% increase in nonmelanoma skin cancer during that time…
In the Journals

Vitamin D levels may affect follicular lymphoma outcomes

May 6, 2015
Low levels of serum vitamin D were associated with greater rates for mortality and disease progression in patients with follicular lymphoma, according to study…
More News Headlines »
CME
Hematology Oncology Case Consults

Diagnosis and Management of Hemophilia

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of the patient with hemophilia supplemented with a case…
More »
Meeting News Coverage Video
VIDEO: Immunotherapies show promise in NSCLC, mesothelioma

VIDEO: Immunotherapies show promise in NSCLC, mesothelioma

May 1, 2015
PHILADELPHIA — Alex A. Adjei, MD, PhD, FACP, senior vice president of clinical research, professor and chair of…
More »
CME
New Advances, New Options: Evaluating the Changing Landscape of Hemophilia

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »
morganatic-roan